기업 규모별 의약품 해외 인허가 과정에서의 장애요인 비교분석
A Comparative Analysis of Barriers for Korean Pharmaceutical Companies in Global Regulatory Affairs by Company Size
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: To provide guidance for agency planning by identifying barriers faced by Korean pharmaceutical companies in global regulatory affairs. Methods: A questionnaire survey on global regulatory affairs was administered by email to personnel at Korean pharmaceutical companies. From a total of 60, 28 responses were collected. Respondents’ companies were classified as small-sized or large-sized, based on whether their annual sales amounted to KRW 100 billion. Results: Small-sized companies were experiencing greater difficulties in receiving drug approvals from advanced countries, particularly during the Investigational New Drug (IND) and Good Manufacturing Practice (GMP) processes. Conclusions: Support measures to specifically help small-sized companies enter more advanced markets and further improved global regulatory guidelines that can meet large-sized companies’ expectations are needed. Moreover, domestic and global regulatory standards should be harmonized to benefit both groups.
Abstract
Objectives: To provide guidance for agency planning by identifying barriers faced by Korean pharmaceutical companies in global regulatory affairs. Methods: A questionnaire survey on global regulatory affairs was administered by email to personnel at Korean pharmaceutical companies. From a total of 60, 28 responses were collected. Respondents’ companies were classified as small-sized or large-sized, based on whether their annual sales amounted to KRW 100 billion. Results: Small-sized companies were experiencing greater difficulties in receiving drug approvals from advanced countries, particularly during the Investigational New Drug (IND) and Good Manufacturing Practice (GMP) processes. Conclusions: Support measures to specifically help small-sized companies enter more advanced markets and further improved global regulatory guidelines that can meet large-sized companies’ expectations are needed. Moreover, domestic and global regulatory standards should be harmonized to benefit both groups.
참고문헌 (18)
- Evaluating SME's Innovation Capability and Analyzing SME Innovation Policy, "C. Y. Lim", Science and Technology Institute, 1~37 (2017)
- Food & drug statistical yearbook(Volume 19), "J. Y. Yang", Ministry of Food and Drug Safety, 38~46 (2017)
- KHIDI Health Industry Statistics Annual 2016, "G.S. Seo", Korea Health Industry Development Institute, 15~33 (2016)
- "2017 Korea Pharmaceutical Industry Guide" (2017)[URL]
- 2017 Regulatory and market information for entering global pharmaceutical market, "S. K. Jung", Korea Health Industry Development Institute, 2~8 (2018)
- Assessing the global trend of drug regulations and formulating a plan for facilitating export of domestic generic drugs to developed countries, Yonsei research affairs and unitversity industry foundation, "E. Cho", Ministry of Food and Drug Safety, 14~15 (2011)
- Diagnosis of Korean pharmaceutical industry’s competence and implications, "J. H. Lee", Korea Institute for International Trade, 1~23, pp.Vol.20 (2019)
- 정재훈, "제약산업의 경영전략, 경영성과에 의약품관련정책이 미치는 영향에 관한 연구", 보건의료산업학회지, 9(4), pp.157~169 (2015), 보건의료산업학회
- Study on export small giants’ growth strategies and related government policies, "B. K. Moon", Korea Institute for International Trade, 1~44, pp.Vol.1 (2018)
- 윤수진, "의약품 해외 수출을 위한 한국 제약산업의 해결과제", 한국임상약학회지, 23(2), pp.106~113 (2013), 한국임상약학회
- K. Y. Yoon, "Regulatory barriers during the approval process of pharmaceutical products in overseas countries", master, pp.2018
- 윤수진, "선진국으로의 의약품 수출 경쟁력: 한국과 인도를 대상으로 한 정책비교분석 연구", 약 학 회 지, 56(2), pp.116~125 (2012), 대한약학회[DOI]
- Analysis of small giant in biopharmaceutical industry (Teva Pharmaceutical) and its implications, "Y. J. Song", Korean Economic Research Institute, 2~12 (2016)
- 이성빈, "국내 제약 산업 수출지원서비스 품질이 기업의 수출 기대치에 미치는 영향", 보건의료산업학회지, 13(3), pp.105~114 (2019), 보건의료산업학회[DOI]